alexa Characterization of the Murine K14-FynY528F Transgenic
ISSN: 2161-0444

Medicinal Chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Characterization of the Murine K14-FynY528F Transgenic SCC Model Provides Novel Therapeutic Insights

Michael D Gober and John T Seykora*

Perelman School of Medicine at the University of Pennsylvania, Department of Dermatology Biomedical Research Building, Philadelphia PA 19104, USA

*Corresponding Author:
John T. Seykora
Associate Professor
Departments of Dermatology and Pathology
Member CAMB Graduate Group
Member Abramson Cancer Center
Perelman School of Medicine at the University of Pennsylvania
Room 1011 BRB II/III, 421 Curie Blvd.Philadelphia, PA 19104, USA
Tel: 215-898- 0170
Fax: 215-573-2143
E-mail: [email protected]

Received date: January 22, 2015; Accepted date: April 09, 2015; Published date: April 11, 2015

Citation: Gober MD, Seykora JT (2015) Characterization of the Murine K14- FynY528F Transgenic SCC Model Provides Novel Therapeutic Insights. Med chem 5:149-151. doi:10.4172/2161-0444.1000256

Copyright: ©2015 Gober MD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Cutaneous squamous cell carcinoma (cSCC) is one of the most common human malignancies. The development of mouse models that accurately recapitulate the human condition is crucial for testing novel therapeutic modalities. In this article we discuss the utility of the K14-Fyn-Y528F transgenic mouse as a model for cSCC and actinic keratosis like precursor lesions and its use in testing novel small molecule kinase inhibitorstopically.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords